Thelansis

 Immune thrombocytopenia (ITP) is a disorder marked by low platelet count, which is crucial for blood clotting due to an autoimmune reaction. This condition manifests as visible skin discoloration caused by blood leaking beneath the skin's surface. Primary ITP arises from immune dysfunction, resulting in low platelet count (<100 × 10^9/L), driven by autoantibodies targeting platelets, T cell-mediated destruction of platelets, and impaired megakaryocyte function. It affects individuals of all ages and genders. In contrast, secondary ITP occurs due to underlying conditions, such as chronic infections (e.g., Helicobacter pylori, HIV) or autoimmune diseases (e.g., lupus, rheumatoid arthritis). In infectious cases, molecular mimicry may lead to the production of cross-reactive autoantibodies against platelets. The primary mechanism in ITP involves IgG autoantibodies binding to platelets and megakaryocytes, mainly targeting surface antigens like GPIIbIIIa and GPIb-IX-V. Phagocytes, pr...

  Immune thrombocytopenia (ITP) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030 Description: Indication name: Immune thrombocytopenia (ITP) Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by a blood abnormality called thrombocytopenia, a shortage of blood cells called platelets needed for normal blood clotting. Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Etiology- The genetic cause of immune thrombocytopenia is unclear. This condition occurs when the body's immune system malfunctions and attacks the body's tissues and organs (autoimmunity). Epidemiology- The incidence of ITP among adults in the USA is estimated to be 3.3 per 100,000 adults/year. The prevalence is 9.5 cases per 100,000. The annual prevalence is estimated at 5.3 per 100,000 among children; because children with ITP usually recover, the number of ...